TUC338 Promotes Diffuse Large B Cell Lymphoma Growth via Regulating EGFR/PI3K/AKT Signaling Pathway

Table 1

Association of TUC338 expression with clinical parameters in DLBCL patients (n = 102).

Parameters	Total (n = 102)	TUC338 expression		value
		Low (n = 51)	High (n = 51)
Age				0.692
≤60	48	23	25
>60	54	28	26
Gender				0.313
Male	41	18	23
Female	61	33	28
Ann Arbor stage				0.016
I-II	44	28	16
III-IV	58	23	35
CHOP-like treatment				<0.001
Response	52	40	12
Nonresponse	50	11	39
IPI				<0.001
0-2	37	28	9
3-5	65	23	42